Medtronic’s Hugo™ robotic-assisted surgery (RAS) system has marked a significant achievement with the success of the EXPAND URO clinical trial in the United States. Focused on minimally invasive urologic procedures like robotic prostatectomy, the trial successfully met its primary safety and effectiveness endpoints, highlighting the system’s potential to become a strong competitor in the robotic surgery market.
The EXPAND URO study involved multiple centers across the U.S. and evaluated the Hugo™ system’s performance in real-world surgical settings. Results showed high procedural success rates, low complication rates and strong surgeon satisfaction, reinforcing the system’s ability to deliver precision and consistency comparable to established robotic platforms.
The Hugo™ system distinguishes itself with a modular and portable design, cloud-connected data and video capture capabilities (through Medtronic’s Touch Surgery™ ecosystem), and a focus on affordability and flexibility, key aspects that could broaden access to robotic surgery worldwide.
Medtronic plans to use the EXPAND URO trial data to support future regulatory submissions and extend Hugo’s applications into other surgical fields, including gynecology and general surgery. Regulatory clearances have already been granted in some international markets, but full U.S. commercial launch will depend on upcoming FDA approvals.
With the robotic surgery market continuing to grow, Medtronic’s progress signals a future where more hospitals and surgeons could adopt robotic systems, offering patients less invasive options and faster recovery times.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. The Hugo™ robotic-assisted surgery system is currently under clinical evaluation in the United States and has not yet received full FDA approval for commercial use. Patients should consult qualified healthcare professionals to understand all available surgical options and outcomes.
